• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Computer Concepts for Medical Device Design

    IVD Manufacturers Are Being Put to the Test

    The New State of Medtech Outsourcing

    The Changing Face of Medtech Surface Treatment

    The Totally Tubular Technologies that Support Medical Devices
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    Vascular Surgeon Imprisoned and Fined for Decade-Long Healthcare Fraud

    Remote Monitoring, Digital Health Help Advance Wound Care Treatment

    MLM Biologics Developing Wound Infection Prevention Device for Military

    NovaScan, PHC Corporation Working on Skin Cancer Detection Device

    Ur24Technology Granted Medicare Reimbursement for External Catheter System
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Computer Concepts for Medical Device Design

    IVD Manufacturers Are Being Put to the Test

    The New State of Medtech Outsourcing

    The Changing Face of Medtech Surface Treatment

    The Totally Tubular Technologies that Support Medical Devices
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Checking Up on Surgical Robotics

    Building a Network: How Synchron Is Developing a New Device—and a New Market

    Six Lessons Learned on Developing a Strong Company Culture

    As Hiring Slows, Companies Look Inward to Fulfill Talent Needs

    Artificial Intelligence: Medtech Opportunity or Health Danger?
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Cirtec Medical

    Medbio LLC

    NDH Medical Inc.

    Fusion Biotec Inc.

    LEMO USA Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    3 Key Elements to Consider When Managing a Medtech Sales Force

    Tech-Enabled Virtual Speech Therapy Improves Speech & Communication Skills

    Practical Strategies for Digitization and Integration in Medtech Manufacturing

    Sensors: The Heart of Minimally Invasive Equipment Technology

    Optimizing UX for the Internet of Medical Things
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Cirtec Medical

    Medbio LLC

    NDH Medical Inc.

    Fusion Biotec Inc.

    LEMO USA Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    Four Common Misperceptions of Accelerated FDA Approval

    ...

    Four Common Misperceptions of Accelerated FDA Approval
    The 21st Century Cures Act aims to spur medical innovation such as “smart” drugs, which use nanotechnology for effective delivery and control of side effects.
    Matthew M. Lowe, Executive Vice President, MasterControl03.07.17
    The 21st Century Cures Act addresses a wide range of healthcare issues, from opioid-abuse prevention to the need for interoperability of electronic health records. Some of the biggest criticisms of the law, however, focused on provisions intended to accelerate the approval of medical products by the U.S. Food and Drug Administration (FDA).

    When it comes to FDA approval processes, the situation is a classic Catch-22. The public wants cheaper medical products sooner. Yet critics sounded the alarm bells when the legislation—which promises a faster approval process that could potentially lower development costs—was signed into law in December 2016.

    Some of the most spirited arguments against the law center on four provisions1 designed to streamline the drug and medical device development and approval processes. These provisions are also the most commonly misunderstood. The first two are specifically targeted toward the medical device sector.

    #1 Section 3051: Breakthrough Devices
    The new law allows the FDA to prioritize approval of medical devices that represent breakthrough technologies. The agency is required to create a guidance that will identify the criteria and the processes for devices designated for expedited development and priority review.

    Misperception: Some people think this creates overly broad standards and sets the bar too low for what are considered “breakthrough” devices. They are afraid this provision might pressure the FDA to hasten the approval process, which could result in poor decisions and less-than-safe devices.
    In fact, this provision will increase the efficiency of the process for reviewing devices for life-threatening diseases or irreversibly debilitating conditions—when there are no other device alternatives.

    First, medtech firms are aware that for their products to qualify as breakthrough devices, they must offer substantial advantages over any existing or similar devices. Critics ought to realize that providing such proof is a heavy burden, making it unlikely for manufacturers to apply for priority review willy-nilly.

    Second, critics should realize that a similar process already exists and the world hasn’t stopped spinning. Section 3051 simply builds on the FDA’s Expedited Access Pathway (EAP)2 for devices that address “unmet medical needs” of patients suffering life-threatening diseases. The FDA has granted 24 devices access to this innovative program, which marked its first full year of operation in 2016.3

    Third, I have always been a huge proponent of giving patients with a terminal condition the choice when it comes to taking on risk with new and developing technologies. Most of these patients have tried everything to no avail, so how can we deny them the hope from potentially breakthrough alternatives? Most of them want to help in accelerating data collection for future patients with the same condition. Ultimately, this means they are taking an active role in their own treatment. If I were in their situation, I know I would want to have a choice.

    #2 Section 2058: Least Burdensome Device Review
    The 21st Century Cures Act provides that FDA employees involved in the review of premarket submissions for devices should apply the “least burdensome requirements.”

    Misperception: Critics think this will divert FDA employee focus away from the safety and efficacy standards of devices, and therefore make the review process less effective.

    Pundits outside the life science industry don’t realize that the “least burdensome” requirement has always been in place. It is neither new nor harmful.

    “Least burdensome” means the minimum required to show effectiveness, but as medtech veterans know, in practice the situation is much stricter. Medical device firms jump through regulatory hoops that can only be characterized as the opposite of “least burdensome.”

    What the new law adds is the requirement that FDA employees be trained properly regarding the meaning and implementation of “least burdensome requirements” and to ensure that they apply the principle consistently. The law calls for a periodic assessment of employee training and requires the FDA ombudsman to conduct an audit to make sure this provision is being followed.

    #3 Section 3022: Real World Evidence
    Real world evidence (RWE) refers to data regarding usage of a drug from sources other than randomized clinical trials, such as ongoing safety surveillance, observational studies, registries, claims, and patient-centered outcomes research activities.

    Misperception: The nonprofit advocacy group Public Citizen4 fears the law will weaken the FDA standards for product approval and lower the bar for the type of evidence needed to comply with post-approval requirements.

    In fact, the new law neither mandates the FDA to use RWE nor changes the agency’s gold standard of approval based on randomized clinical trials, which has been in place since 1962.5 It merely allows the use of real world evidence in some cases, which, if combined with post-approval studies, could accelerate the review process.

    It’s only common sense to use real world evidence. If you are just going for another indication or an expanded indication, why wouldn’t you leverage data from the therapy that is already out in the market? Why replicate safety data for a therapy already in widespread use? This is costly, a waste of time, and delays a new therapy from reaching the market in a timely manner. What’s truly astonishing is the fact that we haven’t been doing this before. No wonder it costs so much to develop a drug in the United States.

    Within two years, the FDA must establish a guidance and a framework for implementing this provision. It must consult with stakeholders, including industry and patient advocacy groups, for the potential use of RWE.

    Dr. Robert Califf, former FDA commissioner, points out that randomized clinical trials and real world evidence are not incompatible. “In fact, the use of randomization within the context of clinical practice will constitute a major advance in evidence generation and we are actively encouraging proposals with this combination of randomized trials conducted in real world practice,” said Dr. Califf.3

    #4 Section 3031: Summary Level Review
    Summary level review refers to “a summary of clinical data that demonstrates the safety and effectiveness of a drug with respect to a qualified indication” to be used to support the approval of a supplemental application. A supplemental application is eligible for review if there is existing data available demonstrating the safety of the drug.

    Misperception: Critics think this section, like real world evidence, will dilute  FDA standards for approving supplemental new drug applications.

    First, when a drug has been approved, it means it has been tested for safety in a healthy patient population. The new law allows the drug manufacturer to leverage that data to obtain another indication for the same drug. It doesn’t make sense to repeat the safety testing, because the data generated will be the same. Repetition only delays getting the new indication to patients and costs millions of dollars that are simply wasted.

    Second, this provision doesn’t mean the FDA cannot or will not ask for full data if necessary. The law allows summary level review, but it doesn’t stop the FDA from asking for full data. The term “qualified indication” implies a built-in screening process, because only indications deemed by the FDA as qualified can take advantage of this provision.

    The FDA is required to be transparent about its use of this provision. It will post the number of applications reviewed and the average time of review, among other things, on the agency’s website.

    Other Misperceptions
    Perhaps the biggest misperception is that the aforementioned provisions are new and untried ideas. In fact, they came from the ongoing efforts of the FDA, the life science industry, advocacy groups, and other stakeholders to improve the approval processes. They build on current efforts to include more patient input in the development process. The provision pertaining to “breakthrough devices,” just like the EAP, gives the patient a voice in the FDA’s decision-making process.

    It took two years and more than 900 pages to finalize the 21st Century Cures Act. It is estimated to cost $6.3 billion upon implementation. It is far from perfect. There is a lot more that the government and the industry must do to accelerate product approval and support medical innovation.

    At the same time, we have to appreciate the law’s ambition and scope, and the great effort in gathering input from stakeholders through the numerous hearings. Most of all, we should appreciate the fact that the new law keeps the ball moving forward in terms of the one thing everybody wants—optimizing, streamlining, and accelerating the FDA review and approval processes—in order to deliver the medical products and treatments to patients sooner rather than later. 

    References
    1. 21st Century Cures Act: http://bit.ly/21curesact.
    2. FDA’s Expedited Access Pathway Program: http://bit.ly/fdaeapp.
    3. “21st Century Cures Act: Making Progress on Shared Goals for Patients,” by FDA Commissioner Robert M. Califf, FDA Voice Blog, Dec. 13, 2016. http://bit.ly/mpo031710.
    4. From Public Citizen’s website: http://bit.ly/mpo031711.
    5. The 1962 Drug Amendments (also known as Kefauver-Harris Amendments), which included GMP requirements, required manufacturers to prove that their products are safe before selling them. The law toughened up FDA inspections and required the reporting of adverse side effects.

    Matthew M. Lowe, executive vice president at MasterControl, is the author of “Convergence of Compliance and Technology: How Technology Has Changed Regulatory Compliance in the Past Decade” (http://bit.ly/mpo031712). He is a mechanical engineer with over a dozen years of medical device experience in product development, product management, and regulatory compliance. He has successfully launched more than a dozen medical devices and has five patents issued. His regulatory compliance experience includes writing a 510(k) that was cleared by the FDA and managing a multisite, multiyear postmarket clinical study for orthopedic devices. 
    Related Searches
    • healthcare
    • standards
    • legislation
    • mechanical
    Related Knowledge Center
    • Digital Health
    • Patient Monitoring
    • Cardiovascular
    • Neurological
    • Surgical
    • Diagnostics
    Suggested For You
    Varian Invests $10M in COTA to Boost Data-Driven Cancer Care Varian Invests $10M in COTA to Boost Data-Driven Cancer Care
    Industry Offers Support for Gottlieb Confirmation Industry Offers Support for Gottlieb Confirmation
    Four Takeaways from Recent Regulatory Audit Changes Four Takeaways from Recent Regulatory Audit Changes
    FDA Designates N8 Medical FDA Designates N8 Medical's CeraShield Endotracheal Tube as a Breakthrough Device
    FDA Clears First Whole Slide Imaging System for Digital Pathology FDA Clears First Whole Slide Imaging System for Digital Pathology
    Collaborating on Custom Materials Development Collaborating on Custom Materials Development
    Extractable/Leachable Chemistry Testing Strategies for Medical Devices Extractable/Leachable Chemistry Testing Strategies for Medical Devices
    Senate Bill Would Improve Medicare LCD Process Senate Bill Would Improve Medicare LCD Process
    First in Man First in Man
    In Pursuit of Device Safety or a Call for Whistleblowers? In Pursuit of Device Safety or a Call for Whistleblowers?
    FDA Approves Increase in Number of Clinical Sites for E-QURE’s Pivotal Trial of BST Device FDA Approves Increase in Number of Clinical Sites for E-QURE’s Pivotal Trial of BST Device
     FlowAid Receives FDA Clearance for the FA100 SCCD FlowAid Receives FDA Clearance for the FA100 SCCD
    Real World Evidence—Mike on Medtech Real World Evidence—Mike on Medtech
    Capillus Laser Therapy Caps Receive FDA Clearance for Over-the-Counter Use Capillus Laser Therapy Caps Receive FDA Clearance for Over-the-Counter Use
    Precision-Based Tech Changing Cancer Detection and Treatment Precision-Based Tech Changing Cancer Detection and Treatment

    Related Breaking News

    • Chronic Disease
      Varian Invests $10M in COTA to Boost Data-Driven Cancer Care

      Varian Invests $10M in COTA to Boost Data-Driven Cancer Care

      Companies will work together to empower cancer clinics with data analytics and decision support tools.
      PR Newswire 11.10.20

    • Industry Offers Support for Gottlieb Confirmation

      Industry Offers Support for Gottlieb Confirmation

      Dr. Gottlieb previously served as the FDA’s deputy commissioner for medical and scientific affairs.
      Sean Fenske, Editor 05.10.17

    • Four Takeaways from Recent Regulatory Audit Changes

      Four Takeaways from Recent Regulatory Audit Changes

      ...
      Alexa Sussman, Content Marketing Writer, EtQ 05.01.17


    • FDA Designates N8 Medical

      FDA Designates N8 Medical's CeraShield Endotracheal Tube as a Breakthrough Device

      Device is a specially-modified endotracheal tube coated with a proprietary ceragenin compound formulation.
      N8 Medical LLC 04.24.17

    • Diagnostics | Digital Health | Electronics | Software & IT
      FDA Clears First Whole Slide Imaging System for Digital Pathology

      FDA Clears First Whole Slide Imaging System for Digital Pathology

      Philips IntelliSite Pathology Solution cleared for primary diagnostic use.
      U.S. Food and Drug Administration 04.13.17

    Loading, Please Wait..

    Trending
    • Philips Names New Supervisory Board Chairman
    • A New Approach To Post-Market Surveillance
    • Healthcare Changes Prompt Medtronic To Merge Sales Force Medtronic, Inc. Is Combining Its U.S. Ca
    • FDA Clears LiveMetric's Wearable Blood Pressure Monitoring Tech
    • Vascular Surgeon Imprisoned And Fined For Decade-Long Healthcare Fraud
    Breaking News
    • Vascular Surgeon Imprisoned and Fined for Decade-Long Healthcare Fraud
    • Remote Monitoring, Digital Health Help Advance Wound Care Treatment
    • MLM Biologics Developing Wound Infection Prevention Device for Military
    • NovaScan, PHC Corporation Working on Skin Cancer Detection Device
    • Ur24Technology Granted Medicare Reimbursement for External Catheter System
    View Breaking News >
    CURRENT ISSUE

    May 2023

    • Computer Concepts for Medical Device Design
    • IVD Manufacturers Are Being Put to the Test
    • The New State of Medtech Outsourcing
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Premium Label & Packaging Solutions Receives Safe Quality Food (SQF) Certification
    Inulinase Enzymes May Benefit Gut Symptoms of FODMAP Digestion
    Verdure Sciences’ Boswellia Ingredient Receives USP Verification
    Coatings World

    Latest Breaking News From Coatings World

    BASF Celebrates 10 Years of its Northeast Research Alliance in the U.S.
    BCF Elects Sharon Harte Its First Female President
    OQ Chemicals Launches Cost-Cutting Program and Organizational Realignment in Germany
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Vascular Surgeon Imprisoned and Fined for Decade-Long Healthcare Fraud
    Remote Monitoring, Digital Health Help Advance Wound Care Treatment
    MLM Biologics Developing Wound Infection Prevention Device for Military
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Catalent Adds New Cryogenic Capabilities at Japanese Facility
    Lifecore Biomedical Enters into $150M New Financing Deal
    WuXi Biologics Receives 2023 ISPE Facility of the Year Award
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    How Robots & Artificial Intelligence are Transforming Unilever's Material Innovation Factory
    Top 10 Most Popular Hair Care Brands in the U.S.—Ranked by Searches
    Aloette Cosmetics Launches Daily Mineral Shield Sunscreen
    Happi

    Latest Breaking News From Happi

    Kérastase Donates $25,000 to The Trevor Project
    Aveda Launches Hypernature Artist Collection
    Amika Leads as the Most Popular Hair Care Brand in the US: Curl Centric
    Ink World

    Latest Breaking News From Ink World

    BCF Elects Sharon Harte First Female President in Its History
    Weekly Recap: INX Digital, Mexar and hubergroup Top This Week’s Stories
    Richnerstutz AG Acquires an EFI VUTEk Q5r Superwide Roll-to-Roll Printer
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Mactac acquires Label Supply, Beontag grows and more
    Sun Chemical releases Spring 2023 Regulatory Newsletter
    Tageos unveils new RAIN RFID inlays
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: Corman, Tosama Develop Biodegradable Plastic Tampon Applicator, Trevira Changes Name
    Suominen Appoints SVP, Transformation Management Office
    Minnesota Signs PFAS Ban in Consumer Products
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    AlloSource Launches AlloMend Duo Acellular Dermal Matrix
    TendoNova Inks Partnership With AcCELLerated Biologics
    Stryker Achieves First Surgeries Using Q Guidance System with Cranial Guidance Software
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Partner Workshops Start Solliance 2.0
    Weekly Recap: Smart Skis, Universal Display Top This Week’s Stories
    Wiliot Appoints Antony Yousefian as VP of Climate & Circularity

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login